| Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies L Boekel, M Steenhuis, F Hooijberg, YR Besten, ZLE van Kempen, ... The Lancet Rheumatology 3 (11), e778-e788, 2021 | 158 | 2021 |
| Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study L Wieske, KPJ van Dam, M Steenhuis, EW Stalman, LYL Kummer, ... The Lancet Rheumatology 4 (5), e338-e350, 2022 | 104 | 2022 |
| Adverse events after first COVID-19 vaccination in patients with autoimmune diseases L Boekel, LY Kummer, KPJ van Dam, F Hooijberg, Z van Kempen, ... The Lancet Rheumatology 3 (8), e542-e545, 2021 | 75 | 2021 |
| Breakthrough SARS-CoV-2 infections with the delta (B. 1.617. 2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy … L Boekel, EW Stalman, L Wieske, F Hooijberg, KPJ van Dam, YR Besten, ... The Lancet Rheumatology 4 (6), e417-e429, 2022 | 51 | 2022 |
| Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases L Wieske, LYL Kummer, KPJ van Dam, EW Stalman, AJ van der Kooi, ... BMC medicine 20 (1), 100, 2022 | 25 | 2022 |
| Longitudinal T-cell responses after a third SARS-CoV-2 vaccination in patients with multiple sclerosis on ocrelizumab or fingolimod V Palomares Cabeza, LYL Kummer, L Wieske, RR Hagen, M Duurland, ... Neurology: Neuroimmunology & Neuroinflammation 9 (4), e1178, 2022 | 22 | 2022 |
| Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate? ZLE van Kempen, L Wieske, EW Stalman, LYL Kummer, PJ van Dam, ... Multiple sclerosis and related disorders 57, 103416, 2022 | 22 | 2022 |
| Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273 NJM Verstegen, RR Hagen, J van den Dijssel, LH Kuijper, C Kreher, ... Elife 11, e77969, 2022 | 18 | 2022 |
| Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study L Boekel, F Hooijberg, EH Vogelzang, YR Besten, M Leeuw, S Atiqi, ... RMD open 8 (1), e002035, 2022 | 16 | 2022 |
| Breakthrough infections with the SARS-CoV-2 omicron (B. 1.1. 529) variant in patients with immune-mediated inflammatory diseases EW Stalman, L Wieske, KPJ van Dam, LY Kummer, ZLE van Kempen, ... Annals of the Rheumatic Diseases 81 (12), 1757-1766, 2022 | 13 | 2022 |
| Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations KPJ van Dam, L Wieske, EW Stalman, LYL Kummer, J Roosen, ... Journal of Autoimmunity 135, 102984, 2023 | 11 | 2023 |
| SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis ZLE van Kempen, EW Stalman, M Steenhuis, LYL Kummer, KPJ van Dam, ... Journal of Neurology, Neurosurgery & Psychiatry 94 (4), 280-283, 2023 | 9 | 2023 |
| T2B! Immunity against SARS-CoV-2 study group. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on … L Wieske, KPJ van Dam, M Steenhuis, EW Stalman, LYL Kummer, ... Lancet Rheumatol 4, e338-50, 2022 | 7 | 2022 |
| Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. Lancet Rheumatol 3: e542–e545 L Boekel, LY Kummer, KPJ van Dam, F Hooijberg, Z van Kempen, ... | 7 | 2021 |
| Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis ZLE van Kempen, L Hogenboom, AA Toorop, M Steenhuis, EW Stalman, ... Annals of Neurology 93 (1), 103-108, 2023 | 6 | 2023 |
| Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity KPJ van Dam, AG Volkers, L Wieske, EW Stalman, LYL Kummer, ... BMC Infectious Diseases 23 (1), 332, 2023 | 2 | 2023 |
| Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases L Wieske, EW Stalman, PJK van Dam, LY Kummer, M Steenhuis, ... Annals of the rheumatic diseases, 2023 | 1 | 2023 |
| Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination KPJ van Dam, L Hogenboom, EW Stalman, LYL Kummer, M Steenhuis, ... Frontiers in neurology 13, 1032830, 2022 | 1 | 2022 |
| Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod ZLE van Kempen, KPJ van Dam, JBD Keijser, EW Stalman, LYL Kummer, ... Multiple Sclerosis Journal, 13524585231207761, 2023 | | 2023 |
| SARS-CoV-2 Delta Breakthrough Infections in Vaccinated Patients with Immune-Mediated Inflammatory Diseases Using Immunosuppressants–Data from Two Controlled Prospective Cohort … L Boekel, E Stalman, L Wieske, F Hooijberg, PJ van Dam, Y Besten, ... | | 2022 |
Theo RispensSanquin Research, University of AmsterdamVerified email at sanquin.nl
